Phase i study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages Academic Article uri icon

Overview

MeSH Major

  • Breast Neoplasms
  • Hemangiosarcoma
  • Neoplasms, Radiation-Induced
  • Neoplasms, Second Primary

abstract

  • Emactuzumab showed specific reduction of immunosuppressive TAMs at the OBD in both treatment arms but did not result in clinically relevant antitumor activity alone or in combination with paclitaxel. (ClinicalTrials.gov Identifier: NCT01494688).

publication date

  • August 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdz163

PubMed ID

  • 31114846

Additional Document Info

start page

  • 1381

end page

  • 1392

volume

  • 30

number

  • 8